Roche pays $250 million to acquire Good Therapeutics and its preclinical cancer therapy
STAT
Sep 7, 2022
Media
News Archive
Good Therapeutics sells PD-1 IL-2 program to Roche for $250M and will march on with a similar name, but in Latin
Endpoints News
Sep 7, 2022
Media
Roche snaps up PD-1-focused Good Therapeutics for $250M; ‘Sky’s the limit’ for spinout
Fierce Biotech
Sep 7, 2022
Media
Good Therapeutics Announces Acquisition of Conditionally Active PD-1-Regulated IL-2 Program by Roche
“Given Roche’s expertise in this field and broad capabilities in oncology, we believe they are a perfect choice for taking this important program forward…”
Targeted Molecule Therapeutics and the Role of Cytokines in Oncological Treatment with John Mulligan
Finding Genius
Feb 14, 2022
Podcast